CA2807585A1 - Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells - Google Patents
Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells Download PDFInfo
- Publication number
- CA2807585A1 CA2807585A1 CA2807585A CA2807585A CA2807585A1 CA 2807585 A1 CA2807585 A1 CA 2807585A1 CA 2807585 A CA2807585 A CA 2807585A CA 2807585 A CA2807585 A CA 2807585A CA 2807585 A1 CA2807585 A1 CA 2807585A1
- Authority
- CA
- Canada
- Prior art keywords
- antigen
- cancer
- antigens
- composition
- viral antigens
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000002671 adjuvant Substances 0.000 title claims abstract description 53
- 210000000612 antigen-presenting cell Anatomy 0.000 title claims description 12
- 230000008685 targeting Effects 0.000 title description 6
- 239000012646 vaccine adjuvant Substances 0.000 title description 5
- 229940124931 vaccine adjuvant Drugs 0.000 title description 5
- 239000000203 mixture Substances 0.000 claims abstract description 93
- 239000000556 agonist Substances 0.000 claims abstract description 56
- 238000000034 method Methods 0.000 claims abstract description 46
- 239000012634 fragment Substances 0.000 claims abstract description 33
- 241000282414 Homo sapiens Species 0.000 claims abstract description 27
- 230000028993 immune response Effects 0.000 claims abstract description 17
- 241001465754 Metazoa Species 0.000 claims abstract description 15
- 230000003308 immunostimulating effect Effects 0.000 claims abstract description 15
- 239000003937 drug carrier Substances 0.000 claims abstract description 5
- 239000000427 antigen Substances 0.000 claims description 230
- 108091007433 antigens Proteins 0.000 claims description 224
- 102000036639 antigens Human genes 0.000 claims description 224
- 108010040721 Flagellin Proteins 0.000 claims description 65
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 65
- 206010028980 Neoplasm Diseases 0.000 claims description 57
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 57
- 230000003612 virological effect Effects 0.000 claims description 55
- 201000001441 melanoma Diseases 0.000 claims description 52
- 102000002689 Toll-like receptor Human genes 0.000 claims description 45
- 108020000411 Toll-like receptor Proteins 0.000 claims description 45
- 210000004443 dendritic cell Anatomy 0.000 claims description 39
- 108090000623 proteins and genes Proteins 0.000 claims description 35
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 34
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims description 34
- 210000004027 cell Anatomy 0.000 claims description 34
- 229960005486 vaccine Drugs 0.000 claims description 34
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 32
- 230000000890 antigenic effect Effects 0.000 claims description 29
- 238000012986 modification Methods 0.000 claims description 22
- 230000004048 modification Effects 0.000 claims description 22
- 210000002307 prostate Anatomy 0.000 claims description 19
- 102100035526 B melanoma antigen 1 Human genes 0.000 claims description 18
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims description 18
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 18
- 241000701806 Human papillomavirus Species 0.000 claims description 18
- 108010063954 Mucins Proteins 0.000 claims description 18
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 18
- 230000001580 bacterial effect Effects 0.000 claims description 18
- 108700025647 major vault Proteins 0.000 claims description 18
- 102000005962 receptors Human genes 0.000 claims description 18
- 108020003175 receptors Proteins 0.000 claims description 18
- 108010008655 Epstein-Barr Virus Nuclear Antigens Proteins 0.000 claims description 17
- 241001138501 Salmonella enterica Species 0.000 claims description 16
- -1 CD31 Proteins 0.000 claims description 14
- 208000032839 leukemia Diseases 0.000 claims description 14
- 101150013553 CD40 gene Proteins 0.000 claims description 13
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 13
- 101710154606 Hemagglutinin Proteins 0.000 claims description 12
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 claims description 12
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 12
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 12
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 12
- 101710176177 Protein A56 Proteins 0.000 claims description 12
- 102100039357 Toll-like receptor 5 Human genes 0.000 claims description 12
- 102000037865 fusion proteins Human genes 0.000 claims description 12
- 108020001507 fusion proteins Proteins 0.000 claims description 12
- 239000000185 hemagglutinin Substances 0.000 claims description 12
- 206010022000 influenza Diseases 0.000 claims description 12
- 238000011321 prophylaxis Methods 0.000 claims description 12
- 241000607626 Vibrio cholerae Species 0.000 claims description 11
- 229940118696 vibrio cholerae Drugs 0.000 claims description 11
- 101000980827 Homo sapiens T-cell surface glycoprotein CD1a Proteins 0.000 claims description 10
- 101000716149 Homo sapiens T-cell surface glycoprotein CD1b Proteins 0.000 claims description 10
- 101000716124 Homo sapiens T-cell surface glycoprotein CD1c Proteins 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 210000002966 serum Anatomy 0.000 claims description 10
- 108090000259 Cyclin D Proteins 0.000 claims description 9
- 102000003910 Cyclin D Human genes 0.000 claims description 9
- 101150029707 ERBB2 gene Proteins 0.000 claims description 9
- 108010008707 Mucin-1 Proteins 0.000 claims description 9
- 102100034256 Mucin-1 Human genes 0.000 claims description 9
- 102100034263 Mucin-2 Human genes 0.000 claims description 9
- 108010008705 Mucin-2 Proteins 0.000 claims description 9
- 108060006580 PRAME Proteins 0.000 claims description 9
- 102000036673 PRAME Human genes 0.000 claims description 9
- 102000003425 Tyrosinase Human genes 0.000 claims description 9
- 108060008724 Tyrosinase Proteins 0.000 claims description 9
- 150000002270 gangliosides Chemical class 0.000 claims description 9
- 238000012737 microarray-based gene expression Methods 0.000 claims description 9
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims description 9
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 claims description 9
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 claims description 9
- 230000000926 neurological effect Effects 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 206010003571 Astrocytoma Diseases 0.000 claims description 7
- 208000018084 Bone neoplasm Diseases 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims description 7
- 206010014596 Encephalitis Japanese B Diseases 0.000 claims description 7
- 208000009889 Herpes Simplex Diseases 0.000 claims description 7
- 208000007514 Herpes zoster Diseases 0.000 claims description 7
- 208000017604 Hodgkin disease Diseases 0.000 claims description 7
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 7
- 208000002979 Influenza in Birds Diseases 0.000 claims description 7
- 201000005807 Japanese encephalitis Diseases 0.000 claims description 7
- 241000710842 Japanese encephalitis virus Species 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
- 206010025323 Lymphomas Diseases 0.000 claims description 7
- 102000043129 MHC class I family Human genes 0.000 claims description 7
- 108091054437 MHC class I family Proteins 0.000 claims description 7
- 208000032271 Malignant tumor of penis Diseases 0.000 claims description 7
- 201000005505 Measles Diseases 0.000 claims description 7
- 208000034578 Multiple myelomas Diseases 0.000 claims description 7
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 7
- 206010033128 Ovarian cancer Diseases 0.000 claims description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 7
- 102100025386 Oxidized low-density lipoprotein receptor 1 Human genes 0.000 claims description 7
- 101710199789 Oxidized low-density lipoprotein receptor 1 Proteins 0.000 claims description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 7
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 7
- 206010034299 Penile cancer Diseases 0.000 claims description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 7
- 206010060862 Prostate cancer Diseases 0.000 claims description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
- 206010037742 Rabies Diseases 0.000 claims description 7
- 241000193448 Ruminiclostridium thermocellum Species 0.000 claims description 7
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 7
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 7
- 206010057644 Testis cancer Diseases 0.000 claims description 7
- 206010064097 avian influenza Diseases 0.000 claims description 7
- 210000003445 biliary tract Anatomy 0.000 claims description 7
- 210000004556 brain Anatomy 0.000 claims description 7
- 210000000621 bronchi Anatomy 0.000 claims description 7
- 210000003679 cervix uteri Anatomy 0.000 claims description 7
- 208000029742 colonic neoplasm Diseases 0.000 claims description 7
- 210000003238 esophagus Anatomy 0.000 claims description 7
- 210000000232 gallbladder Anatomy 0.000 claims description 7
- 206010017758 gastric cancer Diseases 0.000 claims description 7
- 208000005017 glioblastoma Diseases 0.000 claims description 7
- 201000010536 head and neck cancer Diseases 0.000 claims description 7
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 7
- 210000003734 kidney Anatomy 0.000 claims description 7
- 210000000867 larynx Anatomy 0.000 claims description 7
- 210000000088 lip Anatomy 0.000 claims description 7
- 201000007270 liver cancer Diseases 0.000 claims description 7
- 208000014018 liver neoplasm Diseases 0.000 claims description 7
- 210000004072 lung Anatomy 0.000 claims description 7
- 201000005202 lung cancer Diseases 0.000 claims description 7
- 208000020816 lung neoplasm Diseases 0.000 claims description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 7
- 210000000214 mouth Anatomy 0.000 claims description 7
- 210000001989 nasopharynx Anatomy 0.000 claims description 7
- 210000000653 nervous system Anatomy 0.000 claims description 7
- 201000002528 pancreatic cancer Diseases 0.000 claims description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 7
- 210000003800 pharynx Anatomy 0.000 claims description 7
- 210000000664 rectum Anatomy 0.000 claims description 7
- 230000000241 respiratory effect Effects 0.000 claims description 7
- 201000005404 rubella Diseases 0.000 claims description 7
- 201000011549 stomach cancer Diseases 0.000 claims description 7
- 201000003120 testicular cancer Diseases 0.000 claims description 7
- 210000001685 thyroid gland Anatomy 0.000 claims description 7
- 210000003932 urinary bladder Anatomy 0.000 claims description 7
- 210000004291 uterus Anatomy 0.000 claims description 7
- 206010046885 vaginal cancer Diseases 0.000 claims description 7
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 7
- 208000020416 vascular bone neoplasm Diseases 0.000 claims description 7
- 201000011531 vascular cancer Diseases 0.000 claims description 7
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims description 6
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 6
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 6
- 102100028667 C-type lectin domain family 4 member A Human genes 0.000 claims description 6
- 102100028668 C-type lectin domain family 4 member C Human genes 0.000 claims description 6
- 102100028672 C-type lectin domain family 4 member D Human genes 0.000 claims description 6
- 102100028681 C-type lectin domain family 4 member K Human genes 0.000 claims description 6
- 101710183165 C-type lectin domain family 4 member K Proteins 0.000 claims description 6
- 102100040840 C-type lectin domain family 7 member A Human genes 0.000 claims description 6
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 6
- 102100032912 CD44 antigen Human genes 0.000 claims description 6
- 102100035793 CD83 antigen Human genes 0.000 claims description 6
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 claims description 6
- 206010019799 Hepatitis viral Diseases 0.000 claims description 6
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims description 6
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 6
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 6
- 101000766908 Homo sapiens C-type lectin domain family 4 member A Proteins 0.000 claims description 6
- 101000766907 Homo sapiens C-type lectin domain family 4 member C Proteins 0.000 claims description 6
- 101000766905 Homo sapiens C-type lectin domain family 4 member D Proteins 0.000 claims description 6
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 6
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims description 6
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 claims description 6
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims description 6
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 claims description 6
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 claims description 6
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 6
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 6
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 claims description 6
- 101001018258 Homo sapiens Macrophage receptor MARCO Proteins 0.000 claims description 6
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 6
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 6
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 6
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims description 6
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 6
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims description 6
- 102100025304 Integrin beta-1 Human genes 0.000 claims description 6
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 6
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims description 6
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims description 6
- 102100039564 Leukosialin Human genes 0.000 claims description 6
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 6
- 102100033486 Lymphocyte antigen 75 Human genes 0.000 claims description 6
- 101710157884 Lymphocyte antigen 75 Proteins 0.000 claims description 6
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 claims description 6
- 102000043131 MHC class II family Human genes 0.000 claims description 6
- 108091054438 MHC class II family Proteins 0.000 claims description 6
- 102100033272 Macrophage receptor MARCO Human genes 0.000 claims description 6
- 108010031099 Mannose Receptor Proteins 0.000 claims description 6
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 6
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 6
- 108010006232 Neuraminidase Proteins 0.000 claims description 6
- 102000005348 Neuraminidase Human genes 0.000 claims description 6
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims description 6
- 101710192141 Protein Nef Proteins 0.000 claims description 6
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 6
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 6
- 241000607142 Salmonella Species 0.000 claims description 6
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 6
- 230000000172 allergic effect Effects 0.000 claims description 6
- 208000010668 atopic eczema Diseases 0.000 claims description 6
- 108010025838 dectin 1 Proteins 0.000 claims description 6
- 108700004025 env Genes Proteins 0.000 claims description 6
- 108700004026 gag Genes Proteins 0.000 claims description 6
- 208000037797 influenza A Diseases 0.000 claims description 6
- 208000037801 influenza A (H1N1) Diseases 0.000 claims description 6
- 108010061181 influenza matrix peptide (58-66) Proteins 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 108700004029 pol Genes Proteins 0.000 claims description 6
- 201000010740 swine influenza Diseases 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 6
- 201000001862 viral hepatitis Diseases 0.000 claims description 6
- 102000016736 Cyclin Human genes 0.000 claims description 5
- 108050006400 Cyclin Proteins 0.000 claims description 5
- 208000030852 Parasitic disease Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 230000002538 fungal effect Effects 0.000 claims description 5
- 238000001990 intravenous administration Methods 0.000 claims description 5
- 230000003071 parasitic effect Effects 0.000 claims description 5
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 4
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 4
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 4
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 3
- 241000588722 Escherichia Species 0.000 claims description 3
- 241000186781 Listeria Species 0.000 claims description 3
- 241000588653 Neisseria Species 0.000 claims description 3
- 241000187654 Nocardia Species 0.000 claims description 3
- 241000191940 Staphylococcus Species 0.000 claims description 3
- 241000194017 Streptococcus Species 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 3
- 230000030741 antigen processing and presentation Effects 0.000 claims description 3
- 238000007912 intraperitoneal administration Methods 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims description 2
- 102100022338 Integrin alpha-M Human genes 0.000 claims description 2
- 102100024219 T-cell surface glycoprotein CD1a Human genes 0.000 claims description 2
- 102100034343 Integrase Human genes 0.000 claims 4
- 108010060385 Cyclin B1 Proteins 0.000 claims 2
- 102100032340 G2/mitotic-specific cyclin-B1 Human genes 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 abstract description 3
- 101100205847 Mus musculus Srst gene Proteins 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 9
- 102000053602 DNA Human genes 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 238000005304 joining Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 101710109602 Phase 2 flagellin Proteins 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 108010068150 Cyclin B Proteins 0.000 description 3
- 102000002427 Cyclin B Human genes 0.000 description 3
- 102100034353 Integrase Human genes 0.000 description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- 102100034640 PWWP domain-containing DNA repair factor 3A Human genes 0.000 description 3
- 108050007154 PWWP domain-containing DNA repair factor 3A Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229920002477 rna polymer Polymers 0.000 description 3
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 101000651036 Arabidopsis thaliana Galactolipid galactosyltransferase SFR2, chloroplastic Proteins 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 101100284369 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) has-1 gene Proteins 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 108010091769 Shiga Toxin 1 Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000002617 apheresis Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000000837 carbohydrate group Chemical group 0.000 description 2
- 108010045512 cohesins Proteins 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 229940029030 dendritic cell vaccine Drugs 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000000899 immune system response Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical group N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 108010033918 Alanine-glyoxylate transaminase Proteins 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 229940123189 CD40 agonist Drugs 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical class NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 108700020134 Human immunodeficiency virus 1 nef Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 206010024641 Listeriosis Diseases 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 208000034762 Meningococcal Infections Diseases 0.000 description 1
- 206010028885 Necrotising fasciitis Diseases 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000713112 Orthobunyavirus Species 0.000 description 1
- 241000150452 Orthohantavirus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241001495182 Pseudobacteroides cellulosolvens Species 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 208000017757 Streptococcal toxic-shock syndrome Diseases 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 206010044251 Toxic shock syndrome streptococcal Diseases 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 108010084650 alpha-N-arabinofuranosidase Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000009831 antigen interaction Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000003568 cytokine secretion assay Methods 0.000 description 1
- PGUYAANYCROBRT-UHFFFAOYSA-N dihydroxy-selanyl-selanylidene-lambda5-phosphane Chemical compound OP(O)([SeH])=[Se] PGUYAANYCROBRT-UHFFFAOYSA-N 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 108010078428 env Gene Products Proteins 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- QPMJENKZJUFOON-PLNGDYQASA-N ethyl (z)-3-chloro-2-cyano-4,4,4-trifluorobut-2-enoate Chemical compound CCOC(=O)C(\C#N)=C(/Cl)C(F)(F)F QPMJENKZJUFOON-PLNGDYQASA-N 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 108700014844 flt3 ligand Proteins 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 108010072094 gp100(280-288) melanoma antigen peptide Proteins 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001571 immunoadjuvant effect Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 201000007970 necrotizing fasciitis Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K2039/106—Vibrio; Campylobacter; Not used, see subgroups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37376310P | 2010-08-13 | 2010-08-13 | |
| US61/373,763 | 2010-08-13 | ||
| PCT/US2011/047633 WO2012021834A1 (en) | 2010-08-13 | 2011-08-12 | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2807585A1 true CA2807585A1 (en) | 2012-02-16 |
Family
ID=45564978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2807585A Abandoned CA2807585A1 (en) | 2010-08-13 | 2011-08-12 | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20120039916A1 (enExample) |
| EP (1) | EP2603235A4 (enExample) |
| JP (1) | JP2013535508A (enExample) |
| KR (1) | KR20130108295A (enExample) |
| CN (1) | CN103328005A (enExample) |
| AR (1) | AR082686A1 (enExample) |
| AU (1) | AU2011289234B2 (enExample) |
| BR (1) | BR112013002940A2 (enExample) |
| CA (1) | CA2807585A1 (enExample) |
| MX (1) | MX2013001527A (enExample) |
| RU (1) | RU2013110889A (enExample) |
| TW (1) | TWI506035B (enExample) |
| WO (1) | WO2012021834A1 (enExample) |
| ZA (1) | ZA201301013B (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI422594B (zh) | 2007-02-02 | 2014-01-11 | Baylor Res Inst | 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑 |
| CN101820910B (zh) * | 2007-05-03 | 2014-08-06 | 新加坡科技研究局 | 结合细胞内prl-1多肽或prl-3多肽的抗体 |
| TW201247706A (en) * | 2011-03-08 | 2012-12-01 | Baylor Res Inst | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
| US9045542B2 (en) | 2011-08-29 | 2015-06-02 | Baylor Research Institute | Controlling allergy and asthma by activating human DCs via Dectin-1 or toll-like receptor 2 (TLR2) |
| EP2822599A4 (en) * | 2012-03-05 | 2015-12-23 | Univ Duke | VACCINE FORMULATION |
| CN103566377A (zh) * | 2012-07-18 | 2014-02-12 | 上海博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| WO2014031984A1 (en) * | 2012-08-24 | 2014-02-27 | Baylor Research Institute | Immunological detection methods and compositions |
| CN103409451A (zh) * | 2013-06-28 | 2013-11-27 | 扬州维克斯生物科技有限公司 | 一种向树突状细胞dc靶向加载肿瘤抗原肽的方法 |
| EP3013362B1 (en) | 2013-06-28 | 2021-08-04 | Baylor Research Institute | Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis |
| US10202450B2 (en) | 2013-09-05 | 2019-02-12 | Duke University | Nav 1.7 antibodies and methods of using the same |
| CA2936377A1 (en) | 2014-01-10 | 2015-07-16 | Shanghai Birdie Biotech, Inc. | Compounds and compositions for treating egfr expressing tumors |
| AU2015204503B2 (en) | 2014-01-13 | 2020-07-09 | Baylor Research Institute | Novel vaccines against HPV and HPV-related diseases |
| US20160340439A1 (en) * | 2014-01-22 | 2016-11-24 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and Compositions for Antibody and Antibody-loaded Dendritic Cell Mediated Therapy |
| CN106659774A (zh) | 2014-05-16 | 2017-05-10 | 贝勒研究院 | 用于治疗自身免疫和炎性病症的方法和组合物 |
| WO2015187637A1 (en) * | 2014-06-02 | 2015-12-10 | Baylor Research Institute | Methods and compositions for treating allergy and inflammatory diseases |
| US9884921B2 (en) | 2014-07-01 | 2018-02-06 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
| EP4001311B1 (en) | 2014-07-09 | 2025-11-05 | Birdie Biopharmaceuticals Inc. | Anti-pd-l1/pd-1 combinations for treating tumors |
| CN112546238A (zh) | 2014-09-01 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
| CN104689313A (zh) * | 2015-03-04 | 2015-06-10 | 中国科学院海洋研究所 | 大菱鲆cd83分子作为疫苗佐剂的应用 |
| US10624964B2 (en) | 2015-05-01 | 2020-04-21 | The Trustees Of The University Of Pennsylvania | Methods and compositions for stimulating immune response using potent immunostimulatory RNA motifs |
| MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
| CA3002095A1 (en) * | 2015-11-10 | 2017-05-18 | Yale University | Compositions and methods for treating autoimmune diseases and cancers |
| EP3389707B1 (en) | 2015-12-15 | 2025-08-20 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Immunogenic construct comprising an ebv-cell antigen and a targeting moiety and applications thereof |
| CN115252792A (zh) | 2016-01-07 | 2022-11-01 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-egfr组合 |
| CN115554406A (zh) | 2016-01-07 | 2023-01-03 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-cd20组合 |
| CN115350279A (zh) | 2016-01-07 | 2022-11-18 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-her2组合 |
| IL261188B (en) | 2016-03-04 | 2022-08-01 | Jn Biosciences Llc | An anti-tigit antibody that binds to the tigit polypeptide on one or more amino acid residues |
| IL263616B2 (en) | 2016-07-07 | 2025-01-01 | Univ Leland Stanford Junior | Antibody-adjuvant conjugates |
| WO2018140831A2 (en) * | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| CN108727503A (zh) * | 2017-04-18 | 2018-11-02 | 武汉博沃生物科技有限公司 | VZV重组gE-鞭毛素融合蛋白及其制备方法和应用 |
| CN118515666A (zh) | 2017-04-27 | 2024-08-20 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
| CA3067268A1 (en) | 2017-06-23 | 2018-12-27 | Birdie Biopharmaceuticals, Inc. | Crystalline resiquimod monosulfate anhydrate and its preparation and uses |
| WO2019006038A1 (en) * | 2017-06-28 | 2019-01-03 | The Board Of Trustees Of The Leland Stanford Junior University | METHODS AND COMPOSITIONS FOR STIMULATING DECTINE 2 AND CANCER IMMUNOTHERAPY |
| US20210369635A1 (en) * | 2017-11-29 | 2021-12-02 | Adaptive Phage Therapeutics, Inc. | Novel methods of vaccination using icosahedral phage |
| WO2019166432A1 (en) * | 2018-02-28 | 2019-09-06 | F. Hoffmann-La Roche Ag | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer |
| US20220106566A1 (en) * | 2019-01-22 | 2022-04-07 | The Brigham And Women`S Hospital, Inc. | Antigen-Presenting Neutrophil-Derived Dendritic Cells and Methods of Use Thereof |
| AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
| WO2020193718A1 (en) | 2019-03-27 | 2020-10-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Recombinant proteins with cd40 activating properties |
| US20220298255A1 (en) * | 2019-05-31 | 2022-09-22 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | E-cadherin activating antibodies and uses thereof |
| CN114787181A (zh) * | 2019-11-21 | 2022-07-22 | Inserm(法国国家健康医学研究院) | 用抗pd-1/il-15免疫细胞因子靶向pd-1的新型免疫疗法 |
| US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| JP2023525140A (ja) | 2020-05-13 | 2023-06-14 | アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） | Ｏｘ４０活性化特性を有する組換えタンパク質 |
| JP2023528017A (ja) | 2020-05-26 | 2023-07-03 | アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） | 重症急性呼吸器症候群コロナウイルス２（ｓａｒｓ－ｃｏｖ－２）ポリペプチドおよびワクチン目的でのその使用 |
| CR20220611A (es) | 2020-06-02 | 2023-06-07 | Arcus Biosciences Inc | Anticuerpos anti-tigit |
| CN116209678A (zh) | 2020-07-01 | 2023-06-02 | 安尔士制药公司 | 抗asgr1抗体缀合物及其用途 |
| CN111850006B (zh) * | 2020-07-27 | 2022-04-22 | 齐鲁工业大学 | 一种适用于低钙离子浓度的纤维小体对接蛋白组合突变体36865及应用 |
| KR20230107260A (ko) | 2020-11-12 | 2023-07-14 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | Sars-cov-2 스파이크 단백질의 수용체-결합 도메인에 접합되거나 융합된 항체, 및 백신 목적을 위한 이의 용도 |
| US11572407B2 (en) * | 2020-11-18 | 2023-02-07 | Pionyr Immunotherapeutics, Inc. | Anti-MARCO antibodies and uses thereof |
| CA3205280A1 (en) | 2020-12-23 | 2022-06-30 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Chlamydia vaccine based on targeting momp vs4 antigen to antigen presenting cells |
| MX2023008986A (es) | 2021-01-29 | 2023-08-15 | Inst Nat Sante Rech Med | Polipeptidos antigenicos de chlamydia trachomatis y usos de los mismos con fines de vacuna. |
| CN118555970A (zh) * | 2021-11-04 | 2024-08-27 | 总医院有限公司 | 抗间皮素抗体试剂 |
| KR20240103030A (ko) | 2021-11-17 | 2024-07-03 | 인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르 | 범용 사르베코바이러스 백신 |
| WO2024074571A1 (en) | 2022-10-05 | 2024-04-11 | Institut National de la Santé et de la Recherche Médicale | Dc-targeting vaccine against nipah virus infection |
| EP4601682A1 (en) * | 2022-10-13 | 2025-08-20 | The Brigham & Women's Hospital, Inc. | Methods and compositions for improving response to immunotherapy |
| KR102878250B1 (ko) * | 2023-01-11 | 2025-10-31 | 서울대학교산학협력단 | 코리스메이트 뮤테이즈 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 포함하는 암 예방 또는 치료용 조성물 |
| WO2024216189A1 (en) * | 2023-04-13 | 2024-10-17 | The Regents Of The University Of California | Isoform-independent antibodies to lipoprotein(a) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1057915C (zh) * | 1994-09-19 | 2000-11-01 | 中国医学科学院医药生物技术研究所 | 免疫佐剂 |
| TW200303759A (en) * | 2001-11-27 | 2003-09-16 | Schering Corp | Methods for treating cancer |
| US9259459B2 (en) * | 2003-01-31 | 2016-02-16 | Celldex Therapeutics Inc. | Antibody vaccine conjugates and uses therefor |
| WO2007103048A2 (en) * | 2006-03-01 | 2007-09-13 | Regents Of The University Of Colorado | Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity |
| EP2476432B1 (en) * | 2006-03-07 | 2015-08-19 | Vaxinnate Corporation | Compositions that include hemagglutinin, methods of making and methods of use thereof |
| BRPI0807160A2 (pt) * | 2007-02-02 | 2018-09-25 | Baylor Res Institute | vacinas baseadas no direcionamento de antígeno ao dcir expresso em células apresentadoras de antígeno |
| TWI423985B (zh) * | 2007-02-23 | 2014-01-21 | Baylor Res Inst | 利用ｄｅｃｔｉｎ-１活化人類抗原呈現細胞之醫療應用 |
| BRPI0820270A2 (pt) * | 2007-11-07 | 2015-06-16 | Celldex Therapeutics Inc | Anticorpo monoclonal, vetor de expressão, célula, conjugado molecular, composição, uso da composição, método para detectar a presença ou ausência de dec-205 em uma amostra biológica, e, uso de um conjugado molecular. |
| ES2685823T3 (es) * | 2008-07-16 | 2018-10-11 | Baylor Research Institute | Anticuerpos antagonistas anti-CD40 |
| JP2012520073A (ja) * | 2009-03-10 | 2012-09-06 | ベイラー リサーチ インスティテュート | 抗原提示細胞ターゲティングワクチン |
| CN105837691B (zh) * | 2009-03-10 | 2021-06-29 | 贝勒研究院 | 靶向抗原呈递细胞的癌症疫苗 |
| EP2406286B1 (en) * | 2009-03-10 | 2016-05-18 | Baylor Research Institute | Anti-cd40 antibodies and uses thereof |
| US20110274653A1 (en) * | 2010-05-07 | 2011-11-10 | Baylor Research Institute | Dendritic cell immunoreceptors (dcir)-mediated crosspriming of human cd8+ t cells |
-
2011
- 2011-08-12 TW TW100128970A patent/TWI506035B/zh not_active IP Right Cessation
- 2011-08-12 CA CA2807585A patent/CA2807585A1/en not_active Abandoned
- 2011-08-12 CN CN2011800489046A patent/CN103328005A/zh active Pending
- 2011-08-12 RU RU2013110889/10A patent/RU2013110889A/ru unknown
- 2011-08-12 BR BR112013002940A patent/BR112013002940A2/pt not_active IP Right Cessation
- 2011-08-12 KR KR1020137006354A patent/KR20130108295A/ko not_active Withdrawn
- 2011-08-12 JP JP2013524253A patent/JP2013535508A/ja active Pending
- 2011-08-12 MX MX2013001527A patent/MX2013001527A/es not_active Application Discontinuation
- 2011-08-12 EP EP11817128.9A patent/EP2603235A4/en not_active Withdrawn
- 2011-08-12 AR ARP110102955A patent/AR082686A1/es not_active Application Discontinuation
- 2011-08-12 US US13/208,993 patent/US20120039916A1/en not_active Abandoned
- 2011-08-12 AU AU2011289234A patent/AU2011289234B2/en not_active Ceased
- 2011-08-12 WO PCT/US2011/047633 patent/WO2012021834A1/en not_active Ceased
-
2013
- 2013-02-06 ZA ZA2013/01013A patent/ZA201301013B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20120039916A1 (en) | 2012-02-16 |
| JP2013535508A (ja) | 2013-09-12 |
| KR20130108295A (ko) | 2013-10-02 |
| BR112013002940A2 (pt) | 2019-09-24 |
| AR082686A1 (es) | 2012-12-26 |
| RU2013110889A (ru) | 2014-09-20 |
| EP2603235A4 (en) | 2014-04-09 |
| EP2603235A1 (en) | 2013-06-19 |
| ZA201301013B (en) | 2015-10-28 |
| WO2012021834A1 (en) | 2012-02-16 |
| CN103328005A (zh) | 2013-09-25 |
| AU2011289234A1 (en) | 2013-02-21 |
| TWI506035B (zh) | 2015-11-01 |
| TW201208696A (en) | 2012-03-01 |
| AU2011289234B2 (en) | 2014-09-11 |
| MX2013001527A (es) | 2013-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2011289234B2 (en) | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells | |
| US20120231023A1 (en) | Novel Vaccine Adjuvants Based on Targeting Adjuvants to Antibodies Directly to Antigen-Presenting Cells | |
| TWI423985B (zh) | 利用ｄｅｃｔｉｎ-１活化人類抗原呈現細胞之醫療應用 | |
| ES2432357T3 (es) | Anticuerpos enteramente humanos contra 4-1BB humano (CD137) | |
| US20120121592A1 (en) | Targeting Antigens to Human Dendritic Cells Via DC-Asialoglycoprotein Receptor to Produce IL-10 Regulatory T-Cells | |
| US20110274653A1 (en) | Dendritic cell immunoreceptors (dcir)-mediated crosspriming of human cd8+ t cells | |
| JP2025036704A (ja) | キメラ抗原受容体ｔ細胞治療のための組成物およびその使用 | |
| US9885017B2 (en) | Compositions and methods to immunize against hepatitis C virus | |
| US12295986B2 (en) | Combination immunotherapy for treatment of melanoma, colon or non-small cell lung cancers | |
| US20120244155A1 (en) | Dendritic Cells (DCs) Targeting for Tuberculosis (TB) Vaccine | |
| CN102711824A (zh) | 针对朗格汉斯细胞的疫苗 | |
| KR20110036618A (ko) | 극대화된 Ｇａｇ 및 Ｎｅｆ를 수지상 세포에 표적화시킴을 기본으로 하는 ＨＩＶ 백신 | |
| KR20090127886A (ko) | 수지상 세포 렉틴 유사 산화된 ｌｄｌ 수용체-1(ｌｏｘ-1)을 통한 사람 항원제시세포의 활성화 | |
| CN102036677A (zh) | 热休克蛋白gp96的疫苗接种及其使用方法 | |
| JP2005528373A (ja) | 免疫プロトコルにＦｌｔ３リガンドを用いる方法 | |
| EP2374813A1 (en) | Use of phenol-soluble modulins for vaccine development | |
| TW201219053A (en) | Targeting antigens to human dendritic cells via DC-asialoglycoprotein receptor to produce IL-10 regulatory T-cells | |
| Xiao | Dendritic cell-specific vaccine utilizing antibody-mimetic ligand and lentivector system | |
| HK1185792A (en) | Dendritic cell immunoreceptors (dcir)-mediated crosspriming of human cd8+t cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20170814 |